Literature DB >> 1680624

Geometric isomerization of doxepin during its N-demethylation in humans.

H Ghabrial1, C Prakash, U G Tacke, I A Blair, G R Wilkinson.   

Abstract

The N-demethylation of the individual Z-(cis) and E-(trans) isomers of the tricyclic antidepressant doxepin was studied by examining the 0-8 hr serum concentration-time and the 0-72 hr urinary excretion profiles of parent drug and metabolite in eight healthy males who had received a single oral dose consisting of 25 mg each of Z-[2H0]- and E-[2H4]-labeled drug as the hydrochloride salt. Interconversion of doxepin's isomers was not observed but stereoselective excretion was present. Significant amounts of Z-N-desmethyldoxepin were formed and excreted after dosing with E-doxepin, the urinary Z/E ratio ranging from 0.08 to 3.06. A small amount of nondeuterated E-N-desmethyldoxepin was formed from Z-doxepin in most, but not all, subjects. These findings indicate that isomerization occurs during the N-demethylation of doxepin, possibly involving the formation of an intermediate in which the exocyclic double bond is hydrated and then subseqently dehydrated. This novel biotransformation process accounts for the observation that the Z/E plasma concentration ratio of N-desmethyldoxepin is often greater than that of the administered doxepin in patients receiving the drug therapeutically.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1680624

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  2 in total

1.  Stereoselective pharmacokinetics of doxepin isomers.

Authors:  K K Midha; J W Hubbard; G McKay; E M Hawes; E D Korchinski; T Gurnsey; J K Cooper; R Schwede
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

2.  The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19.

Authors:  Sebastian Härtter; Gunnel Tybring; Thomas Friedberg; Harald Weigmann; Christoph Hiemke
Journal:  Pharm Res       Date:  2002-07       Impact factor: 4.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.